Benzinga · Sep 10, 2026
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
IM
NASDAQ · IMNM
Immunome, Inc.
Healthcare · Biotechnology
$23.95
Up+$0.22 (+0.92%)
Updated Sep 16, 2026, 5:22 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.79B
- P/E ratio
- -7.98
- Dividend yield
- 0.00%
- 52-week range
- $17.83 – $30.06
- Volume
- 1.33M
- Avg. volume
- 1.51M
Price performance
IMNM price history
1M range · 20 trading sessions · Daily adjusted prices
IMNM closed at $23.95 after 20 trading sessions, down 13.10% for the selected period.
- Last close
- $23.95
- Period change
- -13.10%
- Period low
- $23.95
- Period high
- $29.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $24.44 | $24.475 | $23.55 | $23.95 | 1.33M |
| Sep 14, 2026 | $24.65 | $25.26 | $24.40 | $24.55 | 744.61K |
| Sep 11, 2026 | $25.32 | $25.73 | $24.60 | $24.67 | 692.56K |
| Sep 10, 2026 | $25.69 | $26.08 | $24.91 | $24.97 | 729.87K |
| Sep 9, 2026 | $26.43 | $26.99 | $26.10 | $26.12 | 784.12K |
| Sep 8, 2026 | $26.15 | $27.245 | $25.91 | $26.81 | 828.62K |
| Sep 4, 2026 | $26.68 | $27.135 | $26.66 | $26.76 | 562.4K |
| Sep 3, 2026 | $27.60 | $28.27 | $26.67 | $27.16 | 796.42K |
| Sep 2, 2026 | $27.56 | $28.485 | $26.81 | $27.33 | 811.1K |
| Sep 1, 2026 | $27.23 | $27.305 | $26.64 | $27.065 | 700.17K |
| Aug 31, 2026 | $27.48 | $27.63 | $27.00 | $27.41 | 1.05M |
| Aug 28, 2026 | $28.45 | $28.77 | $27.40 | $27.57 | 784.51K |
| Aug 27, 2026 | $28.57 | $29.11 | $28.35 | $28.87 | 1.06M |
| Aug 26, 2026 | $29.34 | $29.385 | $28.62 | $28.75 | 559.03K |
| Aug 25, 2026 | $27.88 | $29.72 | $27.88 | $29.385 | 1.93M |
| Aug 24, 2026 | $28.48 | $28.848 | $27.64 | $28.01 | 1.36M |
| Aug 21, 2026 | $28.46 | $29.30 | $28.125 | $28.52 | 848.79K |
| Aug 20, 2026 | $29.13 | $29.15 | $27.89 | $28.08 | 1.03M |
| Aug 19, 2026 | $27.85 | $30.06 | $27.625 | $29.825 | 2.98M |
| Aug 18, 2026 | $27.10 | $27.69 | $26.7598 | $27.56 | 965.34K |
Latest IMNM news
The latest Smart Investors Daily articles mentioning IMNM.
Stock researchCompany · Overview
IMNM research
Overview
Company profile and research snapshot.
Company profile
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $28.25
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | Truist Securities | Buy | — |
| Jul 21, 2026 | Wedbush | Outperform | — |
| Jun 12, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BOTHELL, Wash., September 02, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.
SeekingAlpha · Aug 13, 2026
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
Benzinga · Aug 12, 2026
Truist Securities Maintains Buy on Immunome, Raises Price Target to $38
Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
